PT  - JOURNAL ARTICLE
AU  - Richard Makurumidze
AU  - Jozefien Buyze
AU  - Tom Decroo
AU  - Lutgarde Lynen
AU  - Madelon de Rooij
AU  - Trevor Mataranyika
AU  - Ngwarai Sithole
AU  - Kudakwashe C. Takarinda
AU  - Tsitsi Apollo
AU  - James Hakim
AU  - Wim Van Damme
AU  - Simbarashe Rusakaniko
TI  - Patient and programmatic characteristics, retention and predictors of attrition among patients starting antiretroviral therapy (ART) before and after the implementation of HIV “Treat All” in Zimbabwe
AID  - 10.1101/2020.07.12.20151845
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.07.12.20151845
4099  - http://medrxiv.org/content/early/2020/07/14/2020.07.12.20151845.short
4100  - http://medrxiv.org/content/early/2020/07/14/2020.07.12.20151845.full
AB  - Background Since scale-up of the HIV “Treat All”, evidence on its real-world effect on known predictors of attrition (either death or lost to follow-up) is lacking. We conducted a retrospective study using Zimbabwe ART program data to assess the association between “Treat All” and, patient and programmatic characteristics, retention and predictors of attrition.Methods We used patient-level data from the electronic patient monitoring system (ePMS) from the nine districts which piloted “Treat All”. We compared patient and programme characteristics, retention and predictors of attrition (lost to follow-up, death or stopping ART) in two cohorts; before (April/May 2016) and after (January/February 2017) “Treat All”. Retention was estimated using survival analysis. Predictors of attrition were determined using a multivariable Cox regression model. Interactions were used to assess the change in predictors.Results We analysed 3787 patients, 1738 (45.9%) and 2049 (54.1%) started ART before and after “Treat All”, respectively. The proportion of men was higher after “Treat All” (39.4.% vs 36.2%, p=0.044). Same-day ART initiation was more frequent after “Treat All” (43.2% vs 16.4%; p<0.001) than before. Retention on ART was higher before “Treat All” (p<0.001). Among non-pregnant women and men, the adjusted hazard ratio (aHR) of attrition after “Treat All” compared to before “Treat All” was 1.73 (95%CI: 1.30 - 2.31). The observed hazard of attrition for women being pregnant at ART initiation decreased by 17% (aHR: 1.73*0.48 = 0.83). Being male (vs female; aHR: 1.45; 95%CI: 1.12 - 1.87) and WHO Stage IV (vs WHO Stage I-III; aHR: 2.89; 95%CI: 1.16 - 7.11) predicted attrition both before and after “Treat All” implementation.Conclusion Attrition was higher after “Treat All”; being male, WHO Stage 4, and pregnancy predicted attrition in both before and after Treat All. However, pregnancy became a less strong risk factor for attrition after “Treat All” implementation.”Competing Interest StatementThe authors have declared no competing interest.Funding StatementRichard Makurumidze receives a PhD scholarship grant from the Institute of Tropical Medicine, funded by the Belgian Development Cooperation (DGD). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was submitted for ethical review and approval to the Institutional Review Board (IRB-1257/18) of the Institute of Tropical Medicine, Antwerp, Belgium; University of Zimbabwe Joint Research Ethics Committee (JREC/239/18) and Medical Research Council of Zimbabwe (MRCZ/A/2410). In addition, permission to conduct the study was sought from the Ministry of Health and Child Care. The data were anonymised to maintain privacy and confidentiality.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe study was conducted with routinely collected program data of the Zimbabwe National ART Programme available in an electronic patient management system (ePMS) However, the data is not available on the public domain, and anyone interested in using the data for scientific or academic purpose should contact the Director of the AIDS and TB Program, Ministry of Health and Child Care, Government of Zimbabwe, 2nd Floor, Mukwati Building, Harare, Zimbabwe. Email: atp.director@ymail.com